Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary technologies. ImmBio is developing next-generation vaccines against serious infectious disease targets, utilising its proprietary technology platforms to directly induce immunity via dendritic cells. ImmBio's lead programme is a vaccine against invasive pneumococcal disease, PnuBioVax™, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Kureha Corp. engages in the manufacture and sale of chemical products for pharmaceuticals, agrochemicals, and packaging materials. It operates through the following segments: Functional Products, Chemical Products, Resin Products, Construction-related Business, and Others. The Functional Products segment produces Polyphenylene Sulfide (PPS) resin, Polyvinylidene Fluoride, and carbon products. The Chemical Products segment develops and markets industrial chemicals, pharmaceutical products, and pesticides. The Resin Products segment includes food packaging materials and household goods. The Construction-related Business segment deals with construction and engineering services. The Others segment covers environmental-related businesses and logistics. The company was founded on June 21, 1944 and is headquartered in Tokyo, Japan.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Discovers, develops and commercializes innovative stress protein-based therapeutic vaccines

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Berg is a Swiss private company located in Berg, with subsidiaries in Spain, providing investment services.

Global Gillette manufactures and sells razors, personal care products, batteries, and oral care products. It also provides selected female grooming products, wet shaving, hair epilating devices, batteries, and toothbrushes. Global Gillette was founded in 1901 and is headquartered in Boston, MA.

Aposcience AG is a biopharmaceutical company established in 2008 and headquartered in Vienna.The company is developing innovative therapeutics for regenerative medicine that are based on secretomes of white blood cells isolated from peripheral blood. This approach sets Aposcience apart from the significant number of competitors working on stem cell based approaches. It is in tune with the generally accepted notion that stem cells exert their beneficial effects by paracrine signaling, not by rebuilding tissue per se. In contrast to competitors in the field, the company utilizes for APOSECTM production easily obtainable peripheral blood mononuclear cells as compared to stem cells or stem cell-derived secretomes from bone marrow.